Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of VLA15 Lyme disease vaccine
NL-OMON61187Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Lyme Disease Vaccine Recombinant OspA in Lyme borreliosis, sponsored by Pfizer. Started Sep 2022; status: completed.
02
Drugs
Lyme Disease Vaccine Recombinant OspA
03
Conditions
Lyme borreliosis
Beyond the preview
Go deeper on NL-OMON61187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61187.